

CAYSTON (aztreonam)

Effective Date: 4/22/14

Date Developed: 4/9/14 by Dr. Robert Sterling

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Aztreonam is a monobactam antibacterial with enhanced beta-lactamase stability, targeted to aerobic Gram-negative bacteria, including *Pseudomonas* spp. **Cayston** is administered by inhalation using a nebulizer.

Pre-Authorization Criteria: cystic fibrosis (CF) patients over 7 years old with known infection with *Pseudomonas aeruginosa*

Dosing: 75 mg three times a day for 28 days via nebulizer, after pre-treatment with a bronchodilator

How Supplied: 75 mg in single-use vial to be reconstituted with 1 mL diluent

Contraindications/Warnings: known allergy to aztreonam

Major Adverse Reactions: cough; acute bronchospasm; rebound decrease in FEV1 after course of therapy

Major Drug Interactions: none described

REFERENCES

Retsch-Bogart GZ, Quittner AI, Gibson RL, et al, "Efficacy and Safety of Inhaled Aztreonam Lysine for Airway *Pseudomonas* in Cystic Fibrosis," *Chest*, 2009, 135 (5):1223-32

Stutman HR, Chartrand SA, Tolentino T, et al, "Aztreonam Therapy for Serious Gram-Negative Infections in Children," *Am J Dis Child*, 1986, 140(11):1147-51.

Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. *Pediatr Pulmonol*. 2012;47(12):1147-58.

Zobell JT, Young DC, Waters CD, et al, "Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: VI. Executive Summary," *Pediatr Pulmonol*, 2013, 48(6):525-37.

Bosso JA and Black PG, "The Use of Aztreonam in Pediatric Patients: A Review," *Pharmacotherapy*, 1991, 11(1):20-5

Revision History:

Date Approved by P&T Committee: 4/22/14

Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG